Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

Blood (2024) 144 (4): 402–407.

https://doi.org/10.1182/blood.2023023557

Published: 2024

Includes: Supplemental data

Journal Articles

Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Blood (2023) 142 (Supplement 1): 1961.

https://doi.org/10.1182/blood-2023-180283

Published: 2023

Journal Articles

Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma

Blood (2023) 142 (Supplement 1): 877.

https://doi.org/10.1182/blood-2023-180315

Published: 2023

Journal Articles

The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma

Francesco Maura, Marcella Kaddoura, Alexandra Maria Poos, Anthony Cirrincione, Benjamin Diamond, Kylee H Maclachlan, Bachisio Ziccheddu, Elias K. Mai, Hartmut Goldschmidt, Katja Weisel, Roland Fenk, Gareth J. Morgan, Saad Z Usmani, Ola Landgren, Marc S. Raab, Niels Weinhold

Blood (2023) 142 (Supplement 1): 638.

https://doi.org/10.1182/blood-2023-182267

Published: 2023

Journal Articles

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Blood (2023) 142 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2023-190473

Published: 2023

Journal Articles

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Blood (2023) 142 (Supplement 1): 333.

https://doi.org/10.1182/blood-2023-187467

Published: 2023

Journal Articles

Identifying Causes of Unscheduled Healthcare Interactions and Changes to Patient Disposition in Individuals Receiving Outpatient Commercial Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 3707.

https://doi.org/10.1182/blood-2023-187889

Published: 2023

Journal Articles

Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens

Blood (2023) 142 (Supplement 1): 2024.

https://doi.org/10.1182/blood-2023-190728

Published: 2023

Journal Articles

Single Cell Whole Genome Measurement of Genomic Heterogeneity and Clonal Evolution in Multiple Myeloma

Andrew McPherson, Kylee H Maclachlan, Matthew Myers, Gryte Satas, Ola Landgren, Saad Z Usmani, Sohrab P Shah, Francesco Maura

Blood (2023) 142 (Supplement 1): 4722.

https://doi.org/10.1182/blood-2023-191065

Published: 2023

Journal Articles

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Marios Papadimitriou, Marilena Tauro, Bachisio Ziccheddu, Alexandra Maria Poos, Abdessamad Youssfi Alaoui, Mark B Meads, Kylee H Maclachlan, Saad Z Usmani, Marc S. Raab, Gareth J. Morgan, Niels Weinhold, Kenneth H. Shain, Ola Landgren, Francesco Maura

Blood (2023) 142 (Supplement 1): 639.

https://doi.org/10.1182/blood-2023-184784

Published: 2023

Journal Articles

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 874.

https://doi.org/10.1182/blood-2023-186802

Published: 2023

Journal Articles

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2023-187891

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis

Nezar Mehanna, Andriy Derkach, Billel Gasmi, Theodora Anagnostou, Heather Landau, Oscar Boutros Lahoud, Michael Scordo, Gunjan L. Shah, Hani Hassoun, Kylee H Maclachlan, Malin Hultcrantz, Neha Korde, Sham Mailankody, Urvi A Shah, Carlyn Rose Tan, Saad Z Usmani, Sergio A. Giralt, Alexander Lesokhin, David Chung

Blood (2023) 142 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2023-177960

Published: 2023

Journal Articles

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 4744.

https://doi.org/10.1182/blood-2023-181868

Published: 2023

Journal Articles

A Whole Foods Plant-Based Weight Loss Intervention Improves Quality of Life, Metabolic, Microbiome and Immune Profile in MGUS/SMM As Well As Progression Trajectory in a Subset - the Nutrivention Trial

Blood (2023) 142 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2023-182878

Published: 2023

Journal Articles

Network Modeling of Apoptosis-Related Genes Reveal a High-Risk Cluster in Multiple Myeloma

Anish Kumar Simhal, Kylee H Maclachlan, Saad Z Usmani, Larry Norton, Joseph O. Deasy, Jung Hun Oh, Allen Tannenbaum

Blood (2023) 142 (Supplement 1): 6615.

https://doi.org/10.1182/blood-2023-190337

Published: 2023

Journal Articles

A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2023-179413

Published: 2023

Journal Articles

Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2023-190279

Published: 2023

Journal Articles

Stem Cell Utilization in the Era of Novel Therapies for Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2219.

https://doi.org/10.1182/blood-2023-188103

Published: 2023

NARROW

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma

The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Identifying Causes of Unscheduled Healthcare Interactions and Changes to Patient Disposition in Individuals Receiving Outpatient Commercial Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens

Single Cell Whole Genome Measurement of Genomic Heterogeneity and Clonal Evolution in Multiple Myeloma

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma

A Whole Foods Plant-Based Weight Loss Intervention Improves Quality of Life, Metabolic, Microbiome and Immune Profile in MGUS/SMM As Well As Progression Trajectory in a Subset - the Nutrivention Trial

Network Modeling of Apoptosis-Related Genes Reveal a High-Risk Cluster in Multiple Myeloma

A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy

Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma

Stem Cell Utilization in the Era of Novel Therapies for Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only